Möchten Sie immer auf dem neuesten Stand bleiben?

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with...

Boehringer partners with Simcere to develop a bispecific antibody that simultaneously inhibits two drivers of inflammatory bowel disease.

Boehringer launches clinical trial exploring interleukin-11’s potential to go beyond slowing IPF and restore lung function.

Boehringer and Jazz Pharma partner to combine two unique HER2-targeted approaches, aiming to offer new breast cancer treatment options.

  Not intended for UK audiences  Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2Affecting up to 100,000...

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years.PPF is a rare lung condition, more life-threatening than many...

Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for IT and Global Business Services effective 1 February 2026  Boehringer Ingelheim announced...

The European Medicines Agency’s (EMA’s) Committee for Veterinary Medicinal Products (CVMP) has adopted positive opinions for two Boehringer poultry vaccines against the highly pathogenic H5 avian...

Boehringer has licensed CDR111 from CDR-Life, an antibody-based trispecific M-gager® for autoimmune diseases.

Boehringer has licensed a small molecule program from Kyowa Kirin focused on developing potential treatments for autoimmune diseases.